Drug intelligence / Profile preview

VY-M

Development stage: Preclinical
Lead developer: Vycellix
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

VY-M is an RNA immunomodulator developed by Vycellix. It is designed to be delivered into T cells and natural killer (NK) cells using Avectas' Solupore® non-viral cell engineering platform. The primary goal of VY-M is to enhance the expansion and potency of these immune cells, thereby improving the manufacturing process for cell-based immunotherapies. This includes accelerating production, reducing costs, and shortening the 'vein-to-vein' time for patients, particularly in the context of cancer immunotherapies.

Targets

PTPRC (Receptor-type tyrosine-protein phosphatase C)

Beyond the preview

Go deeper on VY-M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VY-M.

Explore the full profile